Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
Globe Newswire•14/10/2026•08:00 ET
0
Key Highlights
- ➤Adagene (ADAG) CEO Peter Luo to join H.C. Wainwright fireside chat October 15
- ➤Fireside chat scheduled virtually for 1:30–2:00 p.m. ET
- ➤Muzastotug (ADG126) remains in Phase 1b/2 and Phase 2 studies
- ➤Muzastotug targets MSS metastatic colorectal cancer in combination with anti-PD-1 therapy
SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4(th) Annual Immune Cell Engager Virtual Conference being held virtually on October 15, 2026.
H.C. Wainwright 4(th) Annual Immune Cell Engager Virtual Conference Format: Fireside chat Date: October 15, 2026 Time: 1:30 – 2:00 p.m. ET
Get started
Create a free account to read the full story.